Grant: Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI
Université Laval
$21,753.00
Dissecting host-microbiome modifiers of type 2 diabetes risk and complications
EF 2018-19
Résumé
Obesity-linked type 2 diabetes (T2D) is highly prevalent and has an increasing incidence worldwide, negatively affecting lifespan and quality of life and exerting enormous pressure on health systems throughout the world. The gut microbiota (bacteria in the intestine) is now recognized as a major factor that influence the development of obesity and T2D, and alterations in gut microbiota composition can affect inflammation, insulin sensitivity, and glucose homeostasis. Over time, the gut bacteria and their fragments may past the leaky gut of obese diabetic animals, accumulating and even colonizing the blood and extra-intestinal tissues. However, whether translocation of microbes and microbial products also occurs in human obesity and T2D, especially in metabolic tissues (e.g fat, liver) is still unclear.
The overarching goal of this team grant application is to establish an innovative and interdisciplinary microbiome research program, building upon our existing complementary expertise, integrating new concepts and state-of-the-art technologies. This will involve interdisciplinary collaborations from both clinical and basic scientists from 5 universities across Canada and will include substantive contributions from a well balanced mix of early-career, mid-career and senior investigators that will team-up to deliver the following objectives: 1) Define the human gut microbiome of type 2 diabetic (T2D) individuals and determine its impact on gut health and glucose control; 2) Determine the role of human microbes breaching to gut and reaching the circulation and metabolic tissues in the pathogensis of T2D, and the underlying mechanisms by which those microbes can induce complications; and 3) Determine the impact of those human microbiome as key modifiers of the responses to dietary and drug treatments.
Programme
Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
399189
Name
Marette André
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Team Grant : Canadian Microbiome Initiative 2: Research Teams
Projecttitle
Dissecting host-microbiome modifiers of type 2 diabetes risk and complications
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$21,753
Cihrequipment2
$0
Programname2
Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI
Keyworddelim
Anti-Diabetic Drugs; Diabetic Complications; Inflammation; Insulin Resistance; Intestine; Metabolism; Microbiome; Nutrition; Obesity; Type 2 Diabetes
Abstract
Obesity-linked type 2 diabetes (T2D) is highly prevalent and has an increasing incidence worldwide, negatively affecting lifespan and quality of life and exerting enormous pressure on health systems throughout the world. The gut microbiota (bacteria in the intestine) is now recognized as a major factor that influence the development of obesity and T2D, and alterations in gut microbiota composition can affect inflammation, insulin sensitivity, and glucose homeostasis. Over time, the gut bacteria and their fragments may past the leaky gut of obese diabetic animals, accumulating and even colonizing the blood and extra-intestinal tissues. However, whether translocation of microbes and microbial products also occurs in human obesity and T2D, especially in metabolic tissues (e.g fat, liver) is still unclear.
The overarching goal of this team grant application is to establish an innovative and interdisciplinary microbiome research program, building upon our existing complementary expertise, integrating new concepts and state-of-the-art technologies. This will involve interdisciplinary collaborations from both clinical and basic scientists from 5 universities across Canada and will include substantive contributions from a well balanced mix of early-career, mid-career and senior investigators that will team-up to deliver the following objectives: 1) Define the human gut microbiome of type 2 diabetic (T2D) individuals and determine its impact on gut health and glucose control; 2) Determine the role of human microbes breaching to gut and reaching the circulation and metabolic tissues in the pathogensis of T2D, and the underlying mechanisms by which those microbes can induce complications; and 3) Determine the impact of those human microbiome as key modifiers of the responses to dietary and drug treatments.
Competitiondate
201811
Approvedterm2
1 yr 0 mth
Pinamesdelim
Marette, André; Kramer, Caroline K; Lam, Tony K; Raymond, Frederic; Schertzer, Jonathan D
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Nutr Metabolism &Diab~ $21,753~ $0~